Medical Device Global Market Access

Indonesia is enforcing mandatory Halal certification for medical devices, with the first deadline for low-risk Class A devices set for October 17, 2026. This episode explains the requirements from the Halal Product Assurance Agency (BPJPH), which manufacturers are affected, and the scope of the regulation, which covers not only product ingredients but the entire manufacturing process. We outline the critical steps regulatory, quality, and market-access teams must take now to ensure compliance and maintain market access in this key Southeast Asian market.

Key Questions:
- What is the October 17, 2026 deadline for medical devices in Indonesia?
- Which specific device class is affected by this first Halal certification phase?
- Does the Halal requirement apply only to ingredients in the final device?
- What materials trigger the need for Halal certification?
- How does the Halal Product Assurance Agency (BPJPH) regulate this?
- What are the key steps in the Halal certification process for medical devices?
- What should regulatory teams do now to prepare for the deadline?
- How can manufacturers verify the Halal status of their supply chain?
- What are the consequences of non-compliance after the deadline?

Sources:
- https://www.cisema.com/en/a-practical-guide-to-halal-medical-devices-in-indonesia/
- https://emerhub.com/indonesia/halal-certification/
- https://insightof.co.id/2024/05/08/who-2026-7-product-categories-require-mandatory-halal-certification-in-indonesia/
- https://www.linkedin.com/posts/insightof-consulting-indonesia_mandatoryhalal2026-halalcertification-wajibhalaloktober-activity-7243573216892399616-6k_V
- https://www.gxp-cc.com/en/news/indonesia-halal-manufacturing-methods-for-medical-devices-etc/
- https://andi-rox.com/blog/medical-devices-halal-certification-mandatory-in-2026/

How Pure Global can help:
Pure Global provides end-to-end regulatory consulting for MedTech and IVD companies, helping you navigate complex market access challenges like Indonesia's Halal certification requirements. Our local experts and advanced AI tools streamline the development of regulatory strategies, technical dossier compilation, and submissions to authorities worldwide. We act as your local representative in over 30 markets, ensuring your products meet all regional compliance standards from initial registration to post-market surveillance. For help with your global expansion strategy, contact us at info@pureglobal.com or visit https://pureglobal.com. Explore our free AI regulatory tools and global device database at https://pureglobal.ai.

This episode examines the UK MHRA's Device Safety Information (DSI/2026/012), issued on September 29, 2026, which details critical safety risks for wireless cardiotocography (CTG) monitoring systems. We break down the identified risks of signal crossover and dropouts, the MHRA's required actions for healthcare providers, and the significant post-market compliance and risk management implications for manufacturers of RF-enabled medical devices.

Key Questions:
- What specific risks did the MHRA identify for wireless CTG systems in its September 2026 safety alert?
- How does signal crossover differ from signal dropout, and why are both critical safety concerns?
- What actions are now required of UK healthcare professionals using these devices?
- What are the immediate implications for a manufacturer's risk management file (ISO 14971)?
- How should manufacturers update their Instructions for Use (IFU) and training materials in response to this alert?
- Does this MHRA alert require changes to your post-market surveillance (PMS) plan?
- What design considerations should engineering teams prioritize for future wireless medical devices?
- How can manufacturers proactively address RF interference in a clinical setting?

Sources:
- https://www.gov.uk/government/publications/mhra-safety-round-up-september-2026
- https://thomson-walsh.com/mhra-september-2026-safety-roundup-new-compliance-requirements-for-medical-devices/

How Pure Global can help:
Pure Global offers end-to-end regulatory consulting to help MedTech and IVD companies navigate complex global markets. Our experts can assist with updating your risk management files, refining post-market surveillance strategies, and ensuring your technical documentation meets evolving requirements like those from the UK MHRA. We combine local expertise with advanced AI to streamline market access and maintain compliance across 30+ countries. Let us help you get to market faster and stay there. Contact us at info@pureglobal.com, visit https://pureglobal.com, or explore our free AI tools and database at https://pureglobal.ai.

On September 18, 2026, Japan's PMDA released a major update to its guidance for Software as a Medical Device (SaMD). This episode breaks down the key changes in the revised guide, including new requirements for AI/ML and cybersecurity. We analyze what the new PMDA seminar materials and consultation schedule mean for manufacturers' submission strategies and market access timelines, providing practical steps for regulatory and quality teams to ensure compliance.

Key Questions:
- What are the most significant changes in Japan's revised 2026 SaMD guidance?
- How do the new PMDA seminar materials clarify expectations for AI/ML in medical software?
- What are the updated requirements for SaMD cybersecurity documentation in Japan?
- How does the new consultation schedule impact market entry timelines for SaMD?
- What is a 'Programmatic Improvement Plan' and when is it required for SaMD submissions?
- Who is affected by these PMDA SaMD updates?
- What practical steps should my regulatory team take right now to prepare?
- How do Japan's new SaMD rules compare to international standards?

Sources:
- https://www.pmda.go.jp/english/whats-new/0003.html
- https://www.pmda.go.jp/review-services/drug-reviews/about-reviews/devices/0048.html
- https://www.gmp-platform.com/topics/pmda_samd_20260918/

How Pure Global can help:
Pure Global provides end-to-end regulatory consulting for MedTech and IVD companies seeking to enter or expand in global markets. Our experts in Japan and over 30 other countries offer localized regulatory strategy, technical dossier preparation using advanced AI, and in-country representation. We help you navigate complex requirements like the PMDA's updated SaMD guidance to ensure efficient and successful market access. For a streamlined path to global compliance, visit https://pureglobal.com or contact us at info@pureglobal.com. Explore our free AI regulatory tools and global device database at https://pureglobal.ai.

This episode details the UK MHRA's National Patient Safety Alert (NatPSA/2026/005/MHRA) on the risks of death and serious harm from falls involving patient hoists and slings. We cover the specific mechanical and user-related failures identified by the MHRA, the comprehensive actions required of manufacturers and healthcare providers, and the critical compliance deadline of September 29, 2026. Learn the practical steps your quality, regulatory, and clinical teams must take to ensure patient safety and meet the MHRA's requirements.

Key Questions:
- What specific risks did the MHRA identify with patient hoists and slings?
- Who is responsible for implementing the actions in NatPSA/2026/005/MHRA?
- What is the final deadline for compliance with this patient safety alert?
- How can manufacturers ensure their Instructions for Use meet the new expectations?
- What are the essential pre-use checks that all staff must perform?
- How does equipment compatibility contribute to patient falls?
- What steps should healthcare facilities take to audit their current hoist and sling inventory?
- Why is ongoing training and competency assessment critical for preventing accidents?

Sources:
- https://www.gov.uk/government/publications/mhra-safety-round-up-september-2026/mhra-safety-round-up-september-2026

How Pure Global can help:
Pure Global provides comprehensive regulatory consulting for MedTech and IVD companies seeking to access or maintain their presence in global markets. Our experts specialize in navigating complex requirements from authorities like the UK MHRA, offering services in regulatory strategy, technical dossier preparation, and post-market surveillance. We can help you interpret and implement the requirements of safety alerts like NatPSA/2026/005/MHRA, ensuring your products, documentation, and quality systems are fully compliant. Contact us at info@pureglobal.com or visit https://pureglobal.com to learn how we streamline market access. Explore our free AI tools and regulatory database at https://pureglobal.ai.

The Saudi Food and Drug Authority (SFDA) has taken enforcement action against a medical device company for non-compliant advertising, signaling a stricter approach to market surveillance. This episode breaks down the SFDA's announcement on September 7, 2026, the specific violations related to inaccurate and exaggerated claims, and the potential for fines up to SR5 million. We discuss the implications for all manufacturers in the Saudi market and provide practical, actionable steps for regulatory and marketing teams to ensure their promotional materials are compliant.

Key Questions:
- What recent SFDA enforcement action highlights the risks of non-compliant advertising?
- Which types of marketing claims for a mild osteoarthritis device led to penalties?
- What is the maximum fine a company can face for misleading medical device ads in Saudi Arabia?
- Who is responsible for ensuring promotional materials comply with SFDA regulations?
- How does this action affect manufacturers with direct-to-consumer marketing strategies?
- What are the four essential steps your team should take to audit and approve marketing content for the Saudi market?
- Why is simply translating global marketing campaigns a high-risk strategy in the Kingdom?
- How should regulatory and marketing teams collaborate to prevent compliance issues?

Sources:
- https://www.lexisdiligence.com/legal/news/saudi-arabia-sfda-penalises-misleading-medical-device-advertisement-2026-09-07/

How Pure Global can help:
Pure Global provides comprehensive regulatory consulting for MedTech and IVD companies, streamlining global market access. We act as your local representative in over 30 markets, including Saudi Arabia, developing efficient regulatory strategies and managing technical dossier submissions to authorities like the SFDA. Our experts ensure your advertising and promotional materials align with local requirements, mitigating risks of enforcement action. With our AI-powered tools and deep local expertise, we help you maintain compliance throughout the product lifecycle. Contact us at info@pureglobal.com, visit https://pureglobal.com, or explore our free AI tools and database at https://pureglobal.ai to accelerate your market access.